top of page
Applied Innovation,
Improved Products,
Better Life.
ST. LOUIS, MO – October 22, 2025
Gateway Pharma announced the successful completion of Phase 1 clinical trial for Metronidazole Delayed-Release (DR) Capsules, a QIDP-designated candidate for Clostridioides difficile infection (CDI).
-
Low Systemic Exposure
-
High Fecal Concentrations
-
No adverse events reported
Our Mission
Innovating site-specific delivery of antibiotics to combat antibiotic resistance threats
to the United States and the World.
bottom of page